European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
EBAC was delisted on the 2nd of March, 2023.
46 hedge funds and large institutions have $74.3M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 5 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
1.77% more ownership
Funds ownership: 55.68% → 57.45% (+1.8%)
4% more capital invested
Capital invested by funds: $71.7M → $74.3M (+$2.58M)
0% more funds holding
Funds holding: 46 → 46 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$5.12M |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$979K |
| 3 |
CCM
CAAS Capital Management
New York
|
+$947K |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$867K |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$455K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$6.1M |
| 2 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$959K |
| 3 |
AMH
Apollo Management Holdings
New York
|
-$909K |
| 4 |
FTCM
Fir Tree Capital Management
New York
|
-$428K |
| 5 |
EAM
Exos Asset Management
New York
|
-$103K |
EBAC Hedge Fund Activity: Q2 2022 in Review
46 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q2 2022, worth a combined $74.3M — up 3.6% from $71.7M a quarter earlier.
Fund positioning in EBAC was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 5 trimmed.
The largest buyer was Glazer Capital LLC, adding an estimated $5.12M. The largest seller was Citadel Advisors, exiting entirely with an estimated $6.1M sold.
- 46 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $74.3M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q2 2022, up 3.6% quarter-over-quarter.
- 5 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q2 2022 was Glazer Capital LLC, an estimated $5.12M added.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q2 2022 was Citadel Advisors, an estimated $6.1M sold.
Based on aggregated 13F filings for Q2 2022.